<DOC>
	<DOCNO>NCT01677286</DOCNO>
	<brief_summary>The tetracycline antibiotic doxycycline disrupt A beta amyloid fibril ( AB ) Alzheimer 's disease , transthyretin ( ATTR ) amyloid fibrils familial amyloidotic polyneuropathy , immunoglobulin light chain ( AL ) amyloid fibrils transgenic mouse model disease . If untreated , amyloid deposit impair organ function , affect morbidity mortality patient . This single-center , twelve-month , open-label , prospective , pilot phase II study aim determine whether doxycycline reduces amyloid deposit improves organ function patient systemic localized amyloidosis . The investigator plan enroll patient measurable amyloid disease accord internationally-accepted diagnostic criterion . Patients must stable organ function enrollment . Eligible subject receive active treatment amyloidosis affect kidney , heart , aerodigestive tract , peripheral autonomic nervous system ( ) , lung , eye , skin , bladder , breast undergo evaluation baseline , 6 month , 12 month - frequently clinically indicate . Over 45 year experience indicate doxycycline safe , well tolerate antibiotic . The investigator use standard grade system assess doxycycline response follow twelve month treatment .</brief_summary>
	<brief_title>Safety Effect Doxycycline Patients With Amyloidosis</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>Age 18 old Biopsyproven amyloidosis Biochemical clinical evidence amyloid induce endorgan dysfunction Concurrent use tetracycline Ongoing active treatment amyloidosis Pregnancy unwillingness use contraception woman childbearing age Doxycycline drug allergy/hypersensitivity ECOG performance status &gt; 3 NYHA class &gt; 3 Renal insufficiency ( estimate creatinine clearance &lt; 25 ml/min ) Transaminitis ( AST ALT &gt; 5 time upper limit normal ) Diabetes mellitus hemoglobin A1C &gt; 6.2 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>AL Amyloidosis</keyword>
	<keyword>Primary Amyloidosis</keyword>
	<keyword>Hereditary Amyloidosis</keyword>
	<keyword>Familial Amyloidosis</keyword>
	<keyword>SSA Amyloidosis</keyword>
	<keyword>Senile Systemic Amyloidosis</keyword>
	<keyword>AA Amyloidosis</keyword>
	<keyword>Secondary Amyloidosis</keyword>
	<keyword>Localized Amyloidosis</keyword>
	<keyword>Systemic Amyloidosis</keyword>
</DOC>